For many diseases, the tools of medicine are reaching their limits. CRISPR technologies open new avenues for diagnostics and therapies, although the natural source of CRISPR remains largely untapped. Scientists from the...
Liver cancer is the third most common cause of cancer-related deaths worldwide. So far, the treatment options for two types of liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have been...
An international research team from TWINCORE - Centre for Experimental and Clinical Infection Research, a joint facility of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Hannover Medical...
Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes...
The Minister President of Lower Saxony, Stephan Weil, visited the Helmholtz Centre for Infection Research (HZI) today, 4 February 2022. The visit focused on the current challenges and innovative approaches, especially...
Viruses are mostly encountered as pathogens. However, virus-based vaccination platforms can also help to provide protection from different diseases. In a mouse model, researchers from the Helmholtz Centre for Infection...
Principal Investigator Mathias Munschauer aims to better understand SARS-CoV-2. He now receives funding of 1.5 million euros for his research project “COVIDecode” from the European Research Council (ERC). Munschauer is...
Silke Tannapfel, former Administrative Director, will leave the Helmholtz Centre for Infection Research (HZI) in Braunschweig on 31 December 2021 to take on new professional challenges as Ministerial Director in the...
The increasing spread of resistant germs means that formerly highly effective antibiotics are often not successful anymore in treating infectious diseases. To counteract this development, the team led by Prof. Anna...
